A copy of this work was available on the public web and has been preserved in the Wayback Machine. The capture dates from 2020; you can also visit the original URL.
The file type is
Despite being broadly used for a variety of tasks in the clinic, proteomic analysis has limitations that impede its routine use in the analysis of clinical cancer specimens because techniques such as flow cytometry and western blot analysis require laborious preparation steps and large volumes of clinical samples. Researchers at Stanford University and Cell Biosciences Inc. are looking to change that with an automated protein analysis system, and they have developed the first clinically applicable assay for the technology. 1doi:10.1038/scibx.2009.814 fatcat:pkwor5hgofhh3krgxhy2ult74m